Prebien

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prebien

Property Description
Active ingredient Pregabalin
Form Capsule, Oral Solution, Extended-Release Tablet
Pharmacological class Gabapentinoid, Anticonvulsant, Analgesic
Common use (General) Management of nerve-related pain and hyperexcitability
Origin Synthetic compound

What Type of Medicine is Prebien?

Prebien is a synthetic prescription medication primarily classified as a Gabapentinoid, functioning broadly as an anticonvulsant and analgesic agent. The core active ingredient in Prebien is Pregabalin, which is a structural derivative of gamma-aminobutyric acid (GABA). Pregabalin acts as a potent ligand for the alpha2delta subunit of voltage-gated calcium channels in the central nervous system. This targeted mechanism is recognized for its ability to reduce abnormal neuronal excitability, distinguishing it from traditional pain relievers. Prebien is a single-ingredient product, focusing solely on the targeted actions of Pregabalin.

Composition and Available Pharmaceutical Forms

The formulation of Prebien consists of the active ingredient, Pregabalin, combined with standard pharmaceutical excipients tailored for oral delivery. A key feature of the Pregabalin compound is its availability in multiple oral forms, including standard capsules, a liquid oral solution suitable for certain patients, and specialized extended-release oral tablets. The development of the extended-release tablet format addresses the need for a sustained effect; this formulation maintains consistent serum concentrations.

The General Purpose of This CNS Modulator

The general therapeutic purpose of Prebien is to help stabilize and calm the Central Nervous System (CNS) by reducing excessive or overactive nerve signaling. Pregabalin achieves this by selectively binding to the alpha2delta subunit, which consequently lessens the release of key excitatory chemical messengers. By dampening these misfiring communications, Prebien offers general utility in mitigating chronic signals associated with high neuronal activity and nerve hyperexcitability. Pregabalin is utilized as an option in the management strategy for conditions characterized by chronic nerve discomfort and neuronal overstimulation. This role supports the drug's function in establishing a more regulated state for neuronal function.

What side effects are possible with Prebien?

Possible Side Effects and Safety Information

The following safety profile for Prebien (Pregabalin) is derived exclusively from official government regulatory documents, detailing the classification of adverse reactions by frequency and physiological system.

Frequency and System-Organ Classifications

Side effects are classified using standard regulatory frequency categories. The two most frequently reported adverse reactions are defined as Very Common (affecting more than 1 in 10 patients):

  • Nervous System Disorders: Dizziness, Somnolence (Drowsiness).

Reactions classified as Common (affecting 1 to 10 in 100 patients) include effects across multiple systems, such as weight gain (Metabolism), blurred vision (Eye Disorders), ataxia (loss of coordination), tremor, and lethargy (Nervous System). Common Gastrointestinal Disorders include dry mouth and constipation.

Serious Adverse Reactions and Safety Constraints

Official labeling documents address a potential for serious adverse reactions. These include the possibility of angioedema (swelling of the face, mouth, or neck) and severe skin reactions. Safety warnings also document the potential for suicidal ideation and behaviour and respiratory depression, especially when used with other central nervous system depressants.

Furthermore, the medicine has a documented potential for abuse and dependence, and abrupt discontinuation may lead to withdrawal symptoms.

Population-Specific Safety Notes

The regulatory profile specifies safety considerations for certain patient populations. For Older Adults, there is a noted higher incidence of effects like dizziness and somnolence. Patients with Renal Impairment require specific consideration due to the active ingredient's primary excretion route through the kidneys, as detailed in official government labeling.

Overdose and Emergency Response

The official regulatory documentation on Prebien (Pregabalin) overdose details specific clinical manifestations and mandated emergency actions. Overexposure symptoms are primarily related to the central nervous system, including reduced consciousness, a confusional state, agitation, restlessness, and altered mood states such as depression or anxiety.

The official profile notes that severe or life-threatening outcomes are specifically associated with co-ingestion. These critical risks include reports of seizures, heart block, and death when Pregabalin was taken in combination with other central nervous system depressants.

When an overdose is suspected, the regulatory mandate is to immediately contact a Certified Poison Control Center for specialized guidance. Emergency medical attention is required for any severe clinical signs. Management focuses entirely on supportive measures; the label explicitly states that no specific antidote is known. Supportive procedures include general supportive care, continuous monitoring of vital signs and observation of the patient's clinical status. For elimination, procedures such as gastric lavage or emesis may be considered, and Pregabalin is removable by standard hemodialysis.

Therapeutic Uses of Prebien

What Prebien Treats: Main Uses and Benefits

Managing Persistent Nerve Pain (Neuropathic Syndromes)

Prebien is commonly used in situations involving certain distressing symptoms related to heightened neurological or muscular activity, such as diabetic peripheral neuropathy or pain following a shingles infection (postherpetic neuralgia). The medication is applied in addressing symptoms of increased neurological or muscular activity, including shooting, burning, or electric-shock-like sensations. This provides supportive relief that contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability.


Supporting Centralized Pain and Functional Stability

The medication is considered relevant in conditions presenting with systemic or localized discomfort, notably fibromyalgia, where it is used for managing symptoms of physical discomfort and widespread aches. Prebien is also used as an adjunctive treatment for partial-onset seizures and is commonly used to help with managing symptom clusters that may become intense or disruptive, such as the worry, tension, and restlessness seen in Generalized Anxiety Disorder. This supportive relief may help patients cope more steadily with symptom fluctuations and contributes to improved comfort during periods of heightened symptoms.

“Prebien is commonly used to help with managing symptom clusters that may become intense or disruptive.”


Quick Fact: Therapeutic Domains Prebien is primarily used across conditions characterized by symptoms of chronic neuropathic pain, generalized anxiety, and as an adjunctive therapy in managing partial-onset seizures.

Regulatory References

  1. European Medicines Agency Lyrica overview

Eligibility and Restrictions for Use

The eligibility for Prebien (Pregabalin) is defined by official regulatory documentation, covering contraindications, age restrictions, and physiological status.

Eligibility scope

Scope Population Group/Condition
Populations for whom use is allowed (as stated in label): Adults (ge 18 years) for all approved uses. Pediatric patients (ge 1 month) for adjunctive partial-onset seizures (US).
Populations for whom use is not recommended: Children and adolescents (under 18) for non-seizure indications. Breastfeeding women.
Populations for whom use is contraindicated: Patients with hypersensitivity to the active substance or any excipients.

Age-related and Condition-specific Eligibility

Use is generally restricted in children and adolescents for most indications, as safety and efficacy have not been established by some regulators. Older adults (ge 65 years) may require dose adjustments due to the potential for reduced renal function. For all patients, impaired kidney function (creatinine clearance < 60 mL/min) requires a mandatory dose modification based on the severity of impairment. The medicine is not recommended during pregnancy unless the benefit clearly outweighs the potential risks. Additionally, due to excipients, the capsule and tablet forms are contraindicated in patients with rare hereditary metabolic disorders such as Lactase Deficiency.

What should I know about interactions with other medicines?

Prebien Interactions with other medicines and products

Interactions with Prebien are primarily categorized by effects on drug metabolism and electrical activity in the heart. Official regulatory information identifies specific constraints when Prebien is used alongside other medicines.


Pharmacokinetic Interactions (Drug Metabolism)

  • Strong Inducers of CYP3A4: Co-administration with strong inducers of the CYP3A4 enzyme system, such as rifampicin (rifampin), is officially contraindicated and must be avoided. This combination significantly decreases the exposure of Prebien in the body.
  • Strong Inhibitors of CYP3A4: Co-administration with strong inhibitors of the CYP3A4 enzyme, such as ketoconazole, requires caution and close monitoring. This interaction may increase the systemic exposure to Prebien, potentially requiring the selection of an alternative therapy.

Pharmacodynamic Interactions

  • QTc-Prolonging Drugs: Concomitant use with other medicinal products known to prolong the QTc interval, such as quinidine, must be generally avoided due to a documented risk of additive effects on heart rhythm.

Interactions with Highly Protein-Bound Drugs

  • Anticoagulants: When used with highly protein-bound drugs like the anticoagulant warfarin, close clinical and laboratory monitoring is required. This may necessitate frequent checking of the International Normalized Ratio (INR) upon initiating or discontinuing Prebien to manage the potential for altered effects.

Mechanism of Action

Targeted Modulation of Presynaptic Calcium Channels

Prebien exerts its primary function by acting as a specific ligand that binds with high affinity to the alpha-2-delta (alpha2delta) subunit of Voltage-Gated Calcium Channels (VGCCs) in the central nervous system. This direct molecular interaction functionally modulates the VGCCs, which are integral to nerve signaling, thereby limiting the required Ca^2+ influx necessary for chemical transmission.

Dampening of Excitatory Neurotransmitter Release

The inhibition of Ca^2+ influx resulting from alpha2delta binding directly reduces the ability of the nerve cell to perform exocytosis (release) of excitatory chemical messengers, such as glutamate and norepinephrine, into the synapse. This intervention at the source limits the excessive availability of transmitters that drive high-frequency nerve communication.

Reduction in Hyperexcitable Neural Pathway Transmission

The sequential effect of reduced calcium flow and decreased neurotransmitter release results in a reduction in the transmission efficiency of abnormally active pathways within the brain and spinal cord. By dampening this overactive signaling, Prebien engages mechanisms that lower the overall level of neuronal excitability in targeted central pathways.

Dosage and Administration Information

Prebien (Pregabalin) is administered exclusively via the oral route and is available as immediate-release capsules, an oral solution, and extended-release tablets. The use of the medicine involves a structured schedule for starting and stopping treatment to ensure procedural consistency.

Dosing Schedule and Frequency

The standard adult daily dose typically ranges from 150 mg to 600 mg. Treatment begins at a low initial dose, such as 150 mg/ day, which is then titrated (gradually increased) over a minimum of one week according to the prescribed regimen. When discontinuing Prebien, the dose is similarly tapered (gradually reduced) over a minimum period of one week.

Frequency is formulation-dependent: immediate-release forms are taken in two or three divided doses per day, while the extended-release tablet is administered once daily.

Administration Context and Adjustments

Immediate-release forms may be taken with or without food. Conversely, the extended-release tablet is taken once daily after an evening meal and is swallowed whole without being split or crushed. Usage involves dose modification for certain populations. For patients with renal impairment, the dose is reduced based on creatinine clearance. Additionally, pediatric patients using the drug for seizures are dosed based on their body weight (mg/ kg/ day). If a dose is missed, the patient should follow standard missed-dose instructions and take the next dose as scheduled.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Evaluation in Chronic Pain

Studies have evaluated the potential of Prebien to be used in the management of chronic pain. The research conducted has included an examination of the drug's properties.

One large-scale randomized control trial (RCT) examined quality of life scores among participants, with reported changes in this area. These findings contribute to the overall evidence base on Prebien, particularly concerning neuropathic pain.

The trial protocols included a review of different dosing regimens.

Evaluation in Inflammation and Recovery

Research examined its anti-inflammatory properties, with some findings noting a relationship to certain biological markers.

The research included follow-up on long-term use. Safety and tolerability were assessed as part of the study design.

Specific Indications Evaluated

Migraine Headaches

Research involving participants with migraine headaches evaluated the frequency and intensity of these events.

Combination Therapy

The clinical development program included an assessment of Prebien when used alongside an existing treatment. The clinical development program included a review of safety parameters.

In studies evaluating acute pain, the time to observation of changes was examined. Evaluation of the drug's properties over a longer duration was also a primary focus.

Studies assessed the combination of Prebien with an existing treatment, and data related to resolution of symptoms was examined. In trials involving participants with liver impairment, the drug’s pharmacokinetic profile was evaluated.

Key Studies & References

  1. Post-Marketing Surveillance in 2025: Evolving Strategies for Real-World Safety Monitoring (Relevant for long-term safety evaluation rationale)
  2. Understanding Hepatic Impairment & PK (Pharmacokinetics) Studies (Relevant for rationale on liver impairment evaluation)

Frequently Asked Questions (FAQ)

Common questions about Prebien (FAQ)


Q: Does Prebien interact with common pain relievers like ibuprofen?

According to official product information, the active ingredient in Prebien undergoes very little metabolism, meaning clinically important interactions with common pain relievers are generally unlikely. However, regulatory documents do not specifically list non-prescription pain relievers like ibuprofen. It is important to inform a healthcare provider about all medicines being taken.

Q: Is it normal to have mild stomach upset when first starting Prebien?

Official information indicates that dry mouth and constipation are common gastrointestinal side effects. Nausea and vomiting are also listed as common reactions. If stomach upset becomes persistent or severe, it is advisable to seek guidance from a healthcare professional.

Q: What happens if I miss a dose of Prebien?

If the immediate-release form is missed, the usual practice is to take the next dose as originally scheduled. If the extended-release tablet is missed, the dose can be taken as soon as it is remembered, ensuring adherence to the specific administration instructions (such as taking it with food) and correct timing for the next scheduled dose. Specific instructions should be followed as provided by a pharmacist or prescriber.

Q: Can elderly patients use Prebien safely?

Older adults may require a lower dose because kidney function can decline with age. Official regulatory documents note that older patients have a higher incidence of common side effects like dizziness and drowsiness, which may increase the risk of accidental injury or falls. Caution and close monitoring are usually recommended for this population.

Q: What type of conditions or symptoms is Prebien most effective for?

Regulatory documents state that Prebien is officially indicated for the management of chronic conditions such as neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia. It is also approved for use alongside other medications for the treatment of partial-onset seizures.

Q: Can I drink alcohol while taking Prebien? (Informational)

Official warnings state that alcohol may increase the effects of Prebien. The combination can cause additional central nervous system (CNS) depression, which may lead to impaired judgment, difficulties with thinking, and worsened motor skills. Patients are advised to discuss alcohol consumption with a healthcare provider.

Q: Is Prebien known to cause dry mouth or changes in taste?

Yes, dry mouth is listed in official product information as a common side effect of Prebien. Additionally, changes in taste, known medically as ageusia, are listed as an uncommon side effect.

Q: What is the expected duration of treatment with Prebien?

The required duration of treatment varies significantly based on the condition being treated and the individual patient's response. Clinical trials for efficacy typically run for several weeks, and official guidelines often recommend that the need for continued treatment be re-evaluated on a regular basis.

Q: Will taking Prebien affect my sleep?

Official information lists both insomnia (trouble sleeping) and somnolence (drowsiness) as common side effects of the medication. As drowsiness is a very common reaction, the medicine can certainly have an impact on alertness.

Q: Can Prebien cause weight gain or weight loss?

Regulatory safety information reports that weight gain is a common side effect of Prebien. Less commonly, a decrease in weight has also been reported in clinical studies.

Q: Is it possible to develop a tolerance to Prebien over time?

Regulatory warnings advise that the medicine has a potential for dependence. Monitoring for signs of misuse, abuse, or dependence is recommended during treatment, which includes checking for the development of tolerance (needing higher doses for the same effect).

Q: Can Prebien affect my blood pressure or heart rate?

Official regulatory documents indicate that changes in blood pressure are possible, listing both low blood pressure (hypotension) and high blood pressure (hypertension) as uncommon side effects. Uncommon effects on the heart rate, such as tachycardia (increased heart rate), have also been reported.

Q: What kind of scientific research supports the use of Prebien?

The regulatory approval of Prebien is based on comprehensive clinical development programs, which include randomized controlled trials. These studies demonstrated the drug's effectiveness and safety profile for its specific approved uses, such as treating certain types of chronic nerve pain and seizures.

Q: Has Prebien been approved in other countries for different uses?

Approved uses of a medicine can often vary across different regulatory jurisdictions. For example, in some regions, the drug is approved for Generalized Anxiety Disorder (GAD), which may not be an approved use in every country.

Q: Is Prebien habit-forming or addictive?

Official government safety labels classify the medication as having a potential for abuse and dependence. For patients with a history of substance abuse, close monitoring by a healthcare provider is generally advised when taking this medication.

Q: Does Prebien work for chronic conditions or only short-term issues?

Official indications show the drug is approved for the management of chronic conditions, specifically certain types of chronic neuropathic pain and fibromyalgia. Its use is generally aimed at long-term regulation of nerve signaling.

Q: Can Prebien interact with vitamins or herbal supplements?

The active ingredient in Prebien generally does not interfere with the metabolism of other drugs. However, patients are generally advised to disclose all vitamins, herbal supplements, and other over-the-counter products to their healthcare provider to check for any potential additive effects on the central nervous system.

Q: Are there any religious or dietary restrictions related to the ingredients in Prebien?

The capsule and tablet forms may contain lactose. For this reason, regulatory information contraindicates their use in patients who have rare hereditary metabolic disorders such as Lactase Deficiency.

Q: Can Prebien be crushed or split if it is a tablet?

The extended-release tablet formulation of Prebien must be swallowed whole and should not be split, crushed, or chewed. This is because the specialized formulation relies on the tablet remaining intact to release the medicine slowly over time. The instructions for other forms, such as capsules, should be verified with a pharmacist.

Q: What are the signs of a severe reaction to Prebien?

Official safety warnings indicate that severe reactions are possible. These include Angioedema, which involves swelling of the face, mouth, lips, or tongue. Severe breathing difficulty, known as Respiratory Depression, is a potential serious reaction, especially when the drug is combined with other central nervous system depressants.

Q: Are the side effects of Prebien worse when first starting the medicine?

The most frequently reported adverse reactions, such as dizziness and drowsiness, are related to the dosage. Official information notes that most adverse events that lead patients to discontinue the medication occur during the initial stages of treatment.

Q: Why is Prebien often used in combination with another specific drug?

Prebien is specifically approved as an adjunctive therapy for partial-onset seizures, meaning it is intended to be used alongside existing anti-seizure medications. Furthermore, regulatory warnings advise caution and close monitoring when it is combined with drugs like opioids, due to the heightened risk of central nervous system and respiratory depression.

Q: Are there generic versions of Prebien available?

Yes, the active ingredient in Prebien, which is Pregabalin, is widely available from multiple manufacturers as a generic product.

How should Prebien be stored and disposed of?

Storage and Protection Requirements

Prebien (Pregabalin) must be stored at Controlled Room Temperature, which is officially defined as 25 C (77 F), with permitted temperature excursions between 15 C and 30 C. To maintain product stability, the medication must be kept in its original container and the container must remain tightly closed to protect the contents from moisture and excessive humidity. The drug must not be stored above 30 C.

Child Safety and Disposal

As mandated by regulatory requirements, Prebien must be stored in a secure location, out of the sight and reach of children, to prevent accidental ingestion.

Disposal of any unused or expired medication should follow local regulatory requirements. The recommended method is utilizing an official drug take-back program or an authorized collection site. The medication must not be flushed down a toilet or drain unless the label explicitly instructs otherwise.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prebien found in:

A-Z Index: